Gujarat Magazine

(Albany, US), September 14, 2026, DelveInsight’s “Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2036” report offers an in-depth understanding of rheumatoid arthritis, historical and forecasted epidemiology, as well as the market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

To know in detail about the rheumatoid arthritis market outlook, drug uptake, treatment scenario, and epidemiology trends, click here:https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market

Some of the Key Facts of the Rheumatoid Arthritis Market Report

• In January 2025, Rise Therapeutics announced that it had completed dose escalation enrollment stages for both its R-2487 and R-3750 clinical trials, with both studies now initiating planned dose expansion stages.

• According to AstraZeneca’s FY2025 clinical trial appendix, AZD1163 has advanced to Phase II while AZD6912 remains in Phase I, with data for both programs anticipated after 2026.

• Currently marketed therapies for rheumatoid arthritis include upadacitinib (RINVOQ, AbbVie), barticinib (OLUMIANT, Eli Lilly and Company/Incyte), sarilumab (Regeneron/Sanofi), and tofacitinib (Pfizer), among others.

• Upadacitinib (RINVOQ) obtained regulatory approval in the US and EU in 2019, followed by Japan in 2020.

• Barticinib (OLUMIANT) obtained regulatory approval in the EU and Japan in 2017, followed by the US in 2018.

• Emerging therapies such as AZD1163 and AZD6912 (AstraZeneca), ocadusertib (Eli Lilly and Company), R-2487 (Rise Therapeutics), and MYMD-1 (TNF Pharmaceuticals) are advancing through clinical development to expand the treatment paradigm.

• According to DelveInsight’s analysis, the rheumatoid arthritis market size was valued at approximately USD 31,000 million in 2025 and is projected to grow at a modest CAGR of 2% from 2026 to 2036.

• Nearly 1 in 4 Americans, approximately 60 million individuals, are affected by arthritis, with a substantial proportion experiencing chronic pain that significantly impairs daily functioning.

• First-degree relatives of individuals with rheumatoid arthritis have a 2–3-fold increased risk, while relatively low concordance in monozygotic twins (~15–20%) points to a substantial role of non-genetic and environmental factors.

• About 70% of people living with rheumatoid arthritis are women, and 55% are older than 55 years of age, according to the World Health Organization (2023).

• There is currently no cure for rheumatoid arthritis; however, early diagnosis and appropriate treatment enable many patients to achieve extended periods between flares and maintain full, active lives.

• Key Rheumatoid Arthritis Companies: Rise Therapeutics, Taiho Pharmaceutical, AbbVie, Eli Lilly and Company/Incyte, AstraZeneca, and other emerging market players.

• Key Rheumatoid Arthritis Therapies: Barticinib (OLUMIANT), Upadacitinib (RINVOQ), CIMZIA (certolizumab pegol), R-2487, TAS5315, NTM-001, and other emerging therapies.

Rheumatoid Arthritis Overview

Rheumatoid arthritis is a chronic systemic inflammatory autoimmune disease of unknown cause, typically presenting as bilateral, symmetric polyarthritis of the hands and feet, though any synovial joint and extra-articular organs such as the skin, heart, lungs, and eyes may be involved.

The disease is believed to arise in genetically predisposed individuals, such as HLA-DR4/DR1 carriers, following environmental triggers like smoking or infection, leading to an autoimmune response that drives chronic joint inflammation and progressive structural damage.

Diagnosis relies on clinical evaluation supported by inflammatory markers (ESR, CRP) and autoantibodies including rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP), with imaging modalities such as X-ray, ultrasound, and MRI used to assess joint damage and monitor disease progression.

Get a free sample for the Rheumatoid Arthritis Market Forecast, Size & Share Analysis Report.

Rheumatoid Arthritis Epidemiology

The rheumatoid arthritis epidemiology section provides insights into the historical and current patient pool and forecasted trends across the seven major markets (7MM): the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan for the study period 2022–2036.

Rheumatoid Arthritis Epidemiology Segmentation

• Total Prevalent Cases of Rheumatoid Arthritis.

• Total Diagnosed Prevalent Cases of Rheumatoid Arthritis.

• Gender-specific Cases of Rheumatoid Arthritis.

• Age-specific Cases of Rheumatoid Arthritis.

• Severity-specific Cases of Rheumatoid Arthritis.

• Patients on Targeted Therapies of Rheumatoid Arthritis.

• Line-Wise Treated Cases of Rheumatoid Arthritis.

Download the report to understand which factors are driving rheumatoid arthritis epidemiology trends.

Rheumatoid Arthritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential rheumatoid arthritis drugs expected to launch during the forecast period 2022–2036, covering peak performance, factors affecting growth years, patient uptake by therapy, and anticipated sales.

Drug uptake in rheumatoid arthritis continues to be driven by JAK inhibitors and biologic DMARDs, while emerging therapies such as TAS5315 and R-2487 are expected to broaden treatment options as they progress through clinical development.

The report also covers Rheumatoid Arthritis Pipeline Development: https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Rheumatoid Arthritis Marketed and Late-Stage Therapies and Key Companies

Currently, the landscape is anchored by conventional and biologic DMARDs alongside an expanding class of oral JAK inhibitors, with a diverse early-stage pipeline targeting novel immune pathways.

Rheumatoid Arthritis Marketed Therapies

Upadacitinib (RINVOQ): AbbVie

A prescription JAK inhibitor used to treat adults with moderate to severe rheumatoid arthritis in whom methotrexate did not work well or could not be tolerated. It modulates signaling at the point of JAKs, preventing the phosphorylation and activation of STATs. Approved in the US and EU (2019) and Japan (2020).

Barticinib (OLUMIANT): Eli Lilly and Company/Incyte

A JAK inhibitor indicated for adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies. Approved in the EU and Japan (2017) and the US (2018).

Rheumatoid Arthritis Emerging Therapies

TAS5315: Taiho Pharmaceutical

A novel, highly selective BTK inhibitor being evaluated in Phase II in combination with methotrexate for patients with an inadequate response to methotrexate in Japan, targeting inflammation and bone erosion through regulation of B cells, macrophages, and osteoclasts.

R-2487: Rise Therapeutics

A targeted oral immunotherapy in Phase I development designed to induce T regulatory cells and restore immune balance, activating specific immune pathways to reduce inflammatory cytokines that drive autoimmune pathology.

Discover more about therapies set to shape the rheumatoid arthritis market share

Rheumatoid Arthritis Market Drivers

• Rising global disease burden from an aging population and improved diagnosis rates.

• Advancements in targeted biologics, JAK inhibitors, and personalized therapeutic approaches.

• Growing adoption of treat-to-target strategies and early, aggressive intervention.

• Strong pipeline activity and increasing R&D investment across multiple mechanisms of action.

• Supportive clinical guidelines and rising awareness driving earlier diagnosis and treatment.

Rheumatoid Arthritis Market Barriers

• No curative therapy currently available; management remains focused on remission and symptom control.

• Inadequate treatment response and lack of predictive biomarkers for therapy selection.

• Safety and tolerability concerns associated with long-term biologic and JAK inhibitor use.

• Delayed diagnosis and disease heterogeneity complicating early intervention.

• High cost of biologic and targeted synthetic DMARDs affecting affordability and access.

Scope of the Rheumatoid Arthritis Market Report

• Study Period: 2022–2036.

• Historical Year: 2022–2025.

• Forecast Period: 2026–2036.

• Coverage: 7MM (United States, EU4 [Germany, France, Italy, and Spain], the United Kingdom, and Japan).

• Key Rheumatoid Arthritis Companies: Rise Therapeutics, Taiho Pharmaceutical, AbbVie, Eli Lilly and Company/Incyte, AstraZeneca, and other emerging market players.

• Key Rheumatoid Arthritis Therapies: Barticinib (OLUMIANT), Upadacitinib (RINVOQ), CIMZIA (certolizumab pegol), R-2487, TAS5315, NTM-001, and other emerging therapies.

• Therapeutic Assessment: Comprehensive analysis of currently marketed and emerging rheumatoid arthritis therapies.

• Market Dynamics: Detailed evaluation of market drivers, barriers, opportunities, and challenges.

• Competitive Intelligence Analysis: SWOT analysis, conjoint analysis, cost assumptions and pricing analogues, reimbursement landscape, and competitive benchmarking.

• Additional Coverage: Unmet needs, KOL insights, market access strategies, and reimbursement analysis across the 7MM.

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Mehul Malhotra
Email: Send Email
Phone: 09650213330
Address:A-1 NV 89107
City: delhi
State: Indiana
Country: United States
Website: https://www.delveinsight.com/consulting